A randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention compared to treatment as usual for reduction of cannabis use and of relapse in early psychosis (CIRCLE): A study protocol for a randomised controlled trial

Trials

Volumn 17, Issue 1, 2016, Pages

  Johnson, Sonia ^a   Sheridan Rains, Luke ^a   Marwaha, Steven ^b   Strang, John ^c   Craig, Thomas ^c   Weaver, Tim ^d   McCrone, Paul ^c   King, Michael ^a   Fowler, David ^e   Pilling, Stephen ^a   Marston, Louise ^a   Omar, Rumana Z ^a   Craig, Meghan ^a   Hinton, Mark ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MIDDLESEX UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Cannabis; Contingency management; Early intervention; Financial incentives; Psychosis; Substance misuse

Indexed keywords

ADULT; ARTICLE; BEHAVIOR THERAPY; CANNABIS USE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; CONTINGENCY MANAGEMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EARLY INTERVENTION; FEASIBILITY STUDY; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH SERVICE; OUTCOME ASSESSMENT; PSYCHOEDUCATION; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TEST RETEST RELIABILITY; UNITED KINGDOM; URINALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; RECURRENT DISEASE; SAMPLE SIZE;

CANNABIS;

CANNABIS; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; HUMANS; PSYCHOTIC DISORDERS; RECURRENCE; SAMPLE SIZE;

EID: 84996968425     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1620-x     Document Type: Article

References (48)

1. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D, McGorry PD, Schimmelmann BG. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112:141-8.
2. Barnes TE, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 2006;188:237-42.
3. Linszen D, Dingemans P, Lenior M. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273-4.
4. Verdoux H, Liraud F, Gonzales B, Assens F, Abalan F, Van Os J. Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2001;103:347-54.
5. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry. 2006;189:229-34.
6. Walsh E, Buchanan A, Fahy T. Violence and schizophrenia: examining the evidence. Br J Psychiatry. 2002;180:490-5.
7. Kooyman I, Dean K, Harvey S, Walsh E. Outcomes of public concern in schizophrenia. Br J Psychiatry. 2007;191:s29-36.
8. Marwaha S, Johnson S, Bebbington P, Stafford M, Angermeyer MC, Brugha T, Azorin J-M, Kilian R, Hansen K, Toumi M. Rates and correlates of employment in people with schizophrenia living in the UK, France and Germany: findings from the EuroSC study. Br J Psychiatry. 2007;191:30-7.
9. Jeffery D, Ley A, McLaren S, Siegfried N. Psychosocial treatment programmes for people with both severe mental illness and substance misuse. In: The Cochrane Library: Issue 3. Wiley: Chichester; 2004.
10. Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews. 2013;(10). Art. No.: CD001088. doi: 10.1002/14651858.CD001088.pub3. http://www.cochrane.org/CD001088/SCHIZ_psychosocial-interventions-for-people-with-both-severe-mental-illness-and-substance-misuse.
11. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, Schofield N, McGovern J. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry. 2001;158:1706-13.
12. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand. 2007;115:304-9.
13. Archie S, Rush BR, Akhtar-Danesh N, Norman R, Malla A, Roy P, Zipurshy RB. Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophr Bull. 2007;33(6):1354-63.
14. Hides L, Dawe A, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent onset psychosis. Br J Psychiatry. 2006;189:137-43.
15. Mueser K, Drake R. Integrated dual disorder treatment in New Hampshire. In: Graham H, Copello A, Birchwood M, editors. Substance misuse in psychosis: approaches to treatment delivery. London: Wiley; 2003.
16. Barrowclough C, Marshall M, Gregg L, Fitzsimmons M, Tomenson B, Warburton J, Lobban F. A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial. Psychol Med. 2014;44:2749-61.
17. Cahill K, Hartmann-Boyce J, Perera R. Incentives for smoking cessation. Cochrane Database of Systematic Reviews. 2015;(5). Art. No.:CD004307. doi: 10.1002/14651858.CD004307.pub5.
18. Petry NM. Contingency management treatments. Br J Psychiatry. 2006;189(2):97-8.
19. National Institute for Health and Care Excellence (NICE). Clinical guideline on drug misuse in over 16 s: psychosocial interventions. Clinical Guideline 51. London: NICE; 2007.
20. Secades-Villa R, García-Rodríguez O, Higgins S, Fernández-Hermida JR, Carballo JL. Community reinforcement approach plus vouchers for cocaine dependence in a community setting in Spain: six-month outcomes. J Subst Abuse Treat. 2008;34:202-7.
21. Weaver T, Metrebian N, Hellier J, Pilling S, Charles V, Little N, Poovendran D, Mitcheson L, Ryan F, Bowden-Jones O, Dunn J, Glasper A, Finch E, Strang J. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet. 2014;384(9938):153-63.
22. Priebe S, Yeeles K, Bremner S, Lauber C, Eldridge S, Ashby D, David AS, O'Connell N, Forrest A, Burns T. Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial. BMJ. 2013;347:f5847.
23. Bellack AS, Bennett ME, Gearon JS, Brown CH, Ye Yang MS. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006;63:426-32.
24. Sigmon SC, Steingard S, Badger GJ, Anthony SL, Higgins ST. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study. Exp Clin Psychopharmacol. 2000;8:509-17.
25. Sigmon SC, Higgins ST. Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. J Subst Abuse Treat. 2006;30:291-5.
26. Edwards JE, Cocks J, Bott J. Preventative case management in first-episode psychosis. In: McGorry PD, Jackson HJ, editors. The recognition and management of early psychosis: a preventative approach. Cambridge: Cambridge University Press; 1999.
27. Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, McGorry PD. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand. 2006;114:109-17.
28. Budney A, Higgins S, Radonovich K, Novy PL. Adding voucher-based incentive to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol. 2000;68:1051-61.
29. Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. 2006;74:307-16.
30. Sharma P, Murthy P, Bharath MMS. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iranian J Psychiatry. 2012;149-56.
31. Department of Health. The NHS Plan: a plan for investment, a plan for reform. London: The Stationery Office; 2000.
32. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayeroff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-6.
33. Gitlin MJ, Nuechterlein KH, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M. Clinical outcome following neuroleptic discontinuation in remitted recent-onset schizophrenia patients. Am J Psychiatry. 2001;158:1835-42.
34. Sobell L, Sobell M. Timeline Follow-back. In: Allen J, Litten R, editors. Measuring alcohol consumption: psychosocial and biological methods. New Jersey: Humana Press; 1992.
35. Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the Timeline Follow-back for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28(1):154-62.
36. Kay S, Fiszbein R, Opler L. The positive and negative syndrome scale for schizophrenia. Schizophr Bull. 1987;13:261-76.
37. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79:231-8.
38. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring mental health needs. London: Gaskell; 2001.
39. Brazier JE, Roberts JR. The estimation of a preference-based index from the SF-12. Med Care. 2004;42(9):851-9.
40. McCrone P, Patel A, Knapp M, Schene A, Koeter M, Ammadeo F, Ruggeri M, Giessler A, Puschner B, Thornicroft G. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ. 2009;12(1):27-31.
41. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337-43.
42. Salyers MP, Bosworth HB, Swanson JW, Lamb-Pagone J, Osher FC. Reliability and validity of the SF-12 health survey among people with severe mental illness. Med Care. 2000;38(11):1141-50.
43. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53:46-53.
44. StataCorp. Stata Statistical Software: Release 11. College Station: StataCorp LP; 2009.
45. Curtis L. Unit costs of health and social care. PSSRU: Canterbury; 2015.
46. National Institute for Health and Care Excellence (NICE). Psychosis with substance misuse in over 14 s: assessment and management. In: Clinical Guideline 120. London: NICE; 2011.
47. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7:148-56.
48. Promberger M, Brown RC, Ashcroft RE, Marteau TM. Acceptability of financial incentives to improve health outcomes in UK and US samples. J Med Ethics. 2011;37:682-7.